Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy

Protein Pept Lett. 2017;24(5):456-465. doi: 10.2174/0929866524666170120095128.

Abstract

Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.

Keywords: Antibody; antitumor; bispecific antibody (BsAb); cancer therapy; diabody; immunotherapeutic agent.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Bispecific* / chemistry
  • Antibodies, Bispecific* / genetics
  • Antibodies, Bispecific* / therapeutic use
  • Humans
  • Immunotherapy*
  • Mice
  • Neoplasms / therapy*

Substances

  • Antibodies, Bispecific